The KRAS(G12C) Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients

Despite decades of research, efforts to directly target KRAS have been challenging. MRTX849 was identified as a potent, selective, and covalent KRAS(G12C) inhibitor that exhibits favorable drug-like properties, selectively modifies mutant cysteine 12 in GDP-bound KRAS(G12C) and inhibits KRAS-depende...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cancer Discov
Glavni autori: Hallin, Jill, Engstrom, Lars D., Hargis, Lauren, Calinisan, Andrew, Aranda, Ruth, Briere, David M., Sudhakar, Niranjan, Bowcut, Vickie, Baer, Brian R., Ballard, Joshua A., Burkard, Michael R., Fell, Jay B., Fischer, John P., Vigers, Guy P., Xue, Yaohua, Gatto, Sole, Fernandez-Banet, Julio, Pavlicek, Adam, Velastagui, Karen, Chao, Richard C., Barton, Jeremy, Pierobon, Mariaelena, Baldelli, Elisa, Petricoin, Emanuel F., Cassidy, Douglas P., Marx, Matthew A., Rybkin, Igor I., Johnson, Melissa L., Ou, Sai-Hong Ignatius, Lito, Piro, Papadopoulos, Kyriakos P., Jänne, Pasi A., Olson, Peter, Christensen, James G.
Format: Artigo
Jezik:Inglês
Izdano: 2019
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6954325/
https://ncbi.nlm.nih.gov/pubmed/31658955
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-19-1167
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items